Cullinan Oncology (CGEM) Stock Forecast & Price Target

Cullinan Therapeutics is well positioned because its pipeline spans multiple shots on goal in large, underserved markets, with CLN-978 showing durable B-cell depletion and remission signals in RA and SLE, velinotamig advancing in autoimmune cytopenias, and CLN-049 delivering encouraging activity in r/r AML. The company also has a nearer-term commercial catalyst in zipalertinib, which in REZILIENT3 cut progression risk by 50% and improved median PFS to 14.5 months versus 8.5 months, while maintaining an acceptable safety profile. With milestone potential of up to $130 million from Taiho and multiple expected data readouts in 2026, the business has both clinical and financial upside.

Cullinan Therapeutics is facing a challenging competitive backdrop in EGFR Ex20Ins+NSCLC, where ZEGFROVY’s Phase 3 WU-KONG28 data showed strong overall efficacy but appeared less robust outside Asian patients and in those with baseline brain metastases. That raises concern that future regulatory acceptance and commercial traction could be limited by a trial population that may not fully represent the broader 1L market, especially versus competitors with more consistent subgroup performance. More broadly, this reinforces a bearish view on Cullinan’s pipeline quality and execution risk, since its own zipalertinib program is already being compared against stronger late-stage data while the company remains exposed to binary clinical and regulatory outcomes.